Chikungunya Vaccine Succeeds in Phase I: Paving the way for a new generation of vaccines

Themis Bioscience and the Institut Pasteur announce positive chikungunya vaccine results in phase I using revolutionary measles vector Vienna-based Themis Bioscience, and the Paris based Institut Pasteur announced earlier this week a successful phase I trial of their revolutionary chikungunya vaccine. The phase 1 trial of 42 subjects demonstrated the vaccine to be well tolerated and safe. The trial also …

Themis Bioscience’s Vaccine against Chikungunya Successful in Phase 1

Results presented at international conferences in Philadelphia and New Orleans November 20, 2014 The induction of neutralizing antibodies by a prophylactic Chikungunya vaccine candidate has now been confirmed by the final results of a phase 1 clinical trial, as well as its tolerability and safety. Detailed information of the trial has been presented at two international conferences. The vaccine candidate …